Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446717 | 1.00 | TYMP (0.49) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL4820943 | 0.88 | TYMP (0.50) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL7882460 | 0.86 | TYMP (0.49) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL24191239 | 0.85 | ADORA1 (0.49) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL29529385 | 0.84 | TYMP (0.63) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL29574745 | 0.84 | TYMP (0.63) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL1774838 | 0.84 | TYMP (0.63) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL1774839 | 0.84 | TYMP (0.63) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL7871248 | 0.84 | TYMP (0.63) | TYMPADORA1POLBENPP1P2RY1 | |
| SCHEMBL5224854 | 0.84 | TYMP (0.47) | TYMPADORA1POLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | BENNER STEVEN A | 2011-11-10 | — | — | US | disclosed |
| US-8034923-B1 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT | 2011-10-11 | — | — | US | disclosed |
| WO-2010110775-A1 | REAGENTS FOR REVERSIBLY TERMINATING PRIMER EXTENSION | BENNER STEVEN ALBERT (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | RNGTT, POLRMT, DNTT | TYMP 27/4885ADORA1 420/4885POLB 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.